What is Dr. Paul Cox's current title at Neurocept and what are his responsibilities?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The available reporting does not show Dr. Paul Alan Cox holding any title at Neurocept; there is no source here linking him to that company, so his "current title at Neurocept" cannot be confirmed from these materials [1] [2]. What the sources do consistently identify is Paul Alan Cox, Ph.D., as Executive Director (or Executive Director/Executive Director of Brain Chemistry Labs / Brain Chemistry Lab) of Brain Chemistry Labs / The Institute for EthnoMedicine in Jackson Hole, Wyoming, and they describe responsibilities tied to leading a not‑for‑profit research consortium focused on ethnobotany and neurodegenerative disease research [3] [4] [5].
1. Who the reporting actually profiles: Executive director of Brain Chemistry Labs, not Neurocept
Multiple profiles and organizational pages name Paul Alan Cox as Executive Director of Brain Chemistry Labs (also styled Brain Chemistry Lab or The Institute for EthnoMedicine), a not‑for‑profit research organization in Jackson Hole, Wyoming, that pursues ethnobotanical approaches to neurodegenerative disease research [3] [4] [6]. None of the provided sources link him to Neurocept, and the Fortune profile that profiles his work and worldview likewise locates him in a small independent lab in Jackson Hole rather than inside an industry R&D unit such as Neurocept [1].
2. Title on the record in these sources: Executive Director / Executive Director of Brain Chemistry Labs
The Brain Chemistry Labs site and several organizational profiles repeatedly identify Cox as Executive Director or Executive Director of the Brain Chemistry Lab, language echoed in promotional and association materials that describe him leading the Jackson Hole nonprofit and its consortium of scientists [3] [4] [6]. Trade and membership notices that recount his presentations and honors also frame him in that role, reinforcing a consistent public identity tied to the nonprofit rather than to a commercial biotech employer [5].
3. Responsibilities described in the sources: leading research, consortium building, fundraising and public outreach
The cited reporting and organizational pages assign Cox responsibilities that include directing ethnobotanical research into patterns of wellness in indigenous cultures, shepherding drug discovery efforts aimed at Alzheimer’s, ALS and Parkinson’s candidates, coordinating a consortium of scientists, and seeking partnerships to commercialize diagnostics or tests — for example, hopes to secure a diagnostic company partnership to make a test available to neurologists within 18–24 months [1] [3] [4] [5]. These duties imply scientific leadership (shaping research priorities and collaborations), organizational stewardship (running a not‑for‑profit consortium), and external engagement (presenting findings, seeking commercial or diagnostic partnerships) [3] [5].
4. How the work differs from a corporate R&D executive role (and why that matters to the Neurocept question)
Fortune’s longform profile emphasizes Cox’s outsider, grassroots model — a small Jackson Hole lab and an international, flexible consortium that is not embedded in Big Pharma’s corporate apparatus — which contrasts with the typical executive roles inside a for‑profit biotech like Neurocept [1]. That framing matters because holding the title “Executive Director” at a nonprofit research institute entails different responsibilities and governance constraints than an executive title at a private biotech; the sources show Cox functioning as a scientific and organizational director of a nonprofit rather than as a corporate officer of Neurocept [1] [3] [4].
5. Caveats, alternative signals, and gaps in the reporting
While these sources consistently present Cox as Executive Director of Brain Chemistry Labs and outline the responsibilities summarized above, the record here does not include comprehensive, timestamped employment histories or a full CV that might reveal concurrent or newer corporate roles; there is no mention of Neurocept in the supplied snippets or pages [1] [2] [3] [4]. Given that absence, it would be incorrect to assert he holds a current title at Neurocept based solely on this reporting; confirmation would require direct documentation (e.g., Neurocept corporate filings, a Neurocept leadership page, or a contemporaneous bio) which are not present in the provided sources.
6. Bottom line: what can be stated with confidence and what remains unknown
On the evidence supplied, Dr. Paul Alan Cox is identified as Executive Director of Brain Chemistry Labs and is described as leading ethnobotanical, preclinical and translational research efforts, coordinating a consortium of scientists, engaging in outreach and fundraising, and pursuing diagnostic partnerships [3] [4] [5]. Whether he currently holds any title at Neurocept cannot be confirmed from these sources; that specific claim is not supported in the provided reporting [1] [2].